Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. castelobranco@ub.edu
Many patients who receive co-treatment with GnRH agonists (GnRH-a) during chemotherapy treatment preserve their ovarian function and are at risk of unintended pregnancies. Therefore, it is important to offer them effective contraception. Also, pregnancies occurring after cancer therapy in women who received GnRH-a are not associated with adverse neonatal outcomes.